ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / MDWD
NAGE (57) GLAS (18) ACB (54) USNA (50) ⌘ Pro Terminal →

MediWound Ltd. (MDWD) — RQD Stock Rating Cockpit

$13.30 -4.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.18

MediWound Ltd. (MDWD) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $178.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MDWD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MDWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, MediWound Ltd. (NASDAQ: MDWD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $13.30 (-4.04% 1D, market cap $178.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, MDWD ranks #287 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MDWD compare to NAGE and GLAS in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $197.8M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MDWD?
▼

For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #287 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $13.18 (-0.92%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (9)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
$21 Bull$13 Base$10 Bear
📬 FREE MDWD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDWD)Realized 20D OHLCV Swing Band: ±9.2%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY MDWD SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($5.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (60.3) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$12.56+1.1% Next Q
Q2 (-2Q)
46
Grade D$12.70-5% Next Q
Q3 (-1Q)
48
Grade D$12.06+10.3% Next Q
Current
51
Grade D$13.30-1.3% Hist 90D α
Trajectory: D (43) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MDWD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MDWD currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.07) and Max Pain ($13.97) forces dealer call-delta covering toward $20.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MDWD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MDWD Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
60.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE19% OF RANGE
L: $12$13.30H: $20
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on MDWD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (43)

18/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like MDWD
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MDWD)

  • ✓Walkthrough of MDWD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MDWD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.94%▼ DESCENDING CHANNEL
2026-11-02O $13.56H $13.86L $13.30C $13.30VOL 154.4K
RES: $13.96SUP: $11.71SMA50: $13.07SMA200: $15.22
$18.24$16.50$14.75$13.00$11.26RES $13.96SUP $11.71$13.302026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDWD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MDWD Butterfly Map → + Track MDWD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MDWD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MDWD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MDWD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDWD)

Health Care Rank #287 of 1016 ⚔️ NAGE vs MDWD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MDWD vs. NAGE, GLAS, ACB, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MediWound Ltd. (MDWD) ranks #287 by composite RQD confidence (51/100, grade D) and #591 by equity capitalization ($178.9M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with MDWD at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MDWD ACTIVE
MediWound Ltd.
D 51/100 — — — -4.04% $178.9M Benchmark Subject
NAGE
Niagen Bioscience Inc.
D+ 57/100 11.4x 64.3% 16.8% -6.80% $197.8M /nage-vs-mdwd →
GLAS
Glass House Brands Inc. Subordinate Voting Shares
E 18/100 — 42.3% -9.2% -4.39% $200.6M /glas-vs-mdwd →
ACB
Aurora Cannabis Inc.
D+ 54/100 — — — -0.49% $252.8M /acb-vs-mdwd →
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% -0.21% $265.0M /usna-vs-mdwd →

2. MDWD Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

MediWound Ltd. (MDWD) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $178.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MDWD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, MediWound Ltd. (NASDAQ: MDWD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $13.30 (-4.04% 1D, market cap $178.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, MDWD ranks #287 in composite RQD confidence.

How does MDWD compare to NAGE and GLAS in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), MDWD carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NAGE (Niagen Bioscience Inc.) holds a D+ grade (57/100 RQD, P/E 11.4x, ROIC 16.8%, cap $197.8M) and GLAS (Glass House Brands Inc. Subordinate Voting Shares) posts a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MDWD?

For MediWound Ltd. (MDWD), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #287 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MDWD trading relative to its 50-day, 200-day, and 52-week technical levels?

MDWD last traded at $13.30 (-4.04% on volume of 110,109 shares), positioning the stock +1.76% above its 50-day simple moving average ($13.07) and -12.61% below its 200-day simple moving average ($15.22). Across its 52-week range of $11.80 to $19.70, MDWD sits at the 19.0% percentile with a 14-day RSI of 60.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.2% ($12.08 to $14.52).

MDWD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MDWD stock right now?

MediWound Ltd. (MDWD) currently earns a Roarable Rating of D (Sell — SELL) with 51/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is MDWD's 12-month price target and RQD AI Jury consensus?

MDWD's 12-month base price target is $12.88 (range $10.05 to $20.68), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MDWD RQD Cockpit MDWD 12M Forecast MDWD Earnings & Move MDWD Dividends & DRIP MDWD Insiders & 13F MDWD Whale Options MDWD Profit Sankey MDWD News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MDWD — MediWound Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:17:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MediWound Ltd. scores 51 out of 100, earning a "D" grade and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:

  • Fundamental Cash Engine (12 / 20): Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. For a prospective investor, this means the rating reports no measurable return on invested capital and no free-cash-flow yield at the current price, so the valuation case cannot lean on cash generation as reported in this data.
  • Whale 13F Flow (9 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The sub-score sits below midpoint, indicating weaker institutional support signals in this dataset.
  • Insider Conviction (9 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The below-midpoint score contrasts with the news headline noting insider acquisitions (see Recent Catalysts), an apparent tension an investor should verify directly.
  • Macro Regime Fit (8 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. The low score suggests the stock's regime alignment is weak in this framework.
  • Forensic Balance Sheet (13 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating the balance-sheet profile is comparatively more stable than the cash and flow pillars.

Net implication: the upside case rests mainly on balance-sheet resilience and any catalyst-driven re-rating; the valuation tradeoff is that the cash-return and flow pillars do not currently support the price on the metrics provided.

Recent Catalysts & News Wire Analysis

  • Earnings event (YELLOW, MARKET WIRE): A live webcast on MediWound's third-quarter results starts Nov. 12 at 8:30 a.m. ET, per the Recent News feed.
  • Insider buying headline (YELLOW, MARKET WIRE): A Simply Wall St headline titled "Favourable Signals For MediWound: Numerous Insiders Acquired Stock" appears in the feed.
  • Q3 2026 reporting notice (YELLOW, MARKET WIRE): A GlobeNewswire item notes MediWound will report third-quarter 2026 results.
  • Risk watch (RED, RISK WATCH): A Stock Traders Daily item titled "(MDWD) Risk Channels and Responsive Allocation" is flagged RED in the feed.
  • Price action catalyst (GREEN, CATALYST): A headline reports the stock jumped 5.66% to $13.26 as buyers tested upper resistance, flagged GREEN.
  • Other feed items: A Yahoo! Finance Canada seasonal-returns item referencing Fennec Pharmaceuticals (FRX.TO) is tagged YELLOW and is not company-specific to MDWD.
  • Butterfly Supply-Chain Graph: Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream links are recorded, and the supply chain is listed as NONE. Sector correlations and 2nd-order bottlenecks are therefore not available in source data. A prospective investor should note that the absence of mapped dependencies means ripple effects from suppliers, customers, or peers cannot be assessed from this dataset.

Open Questions

  • What are MediWound's reported revenue, operating income, and net income by period, given that the financials section is empty?
  • Why do the 0% margins, ROIC, and FCF yield appear in the market data, and do they reflect actual reported results or missing inputs?
  • Do the reported insider purchases (per the news headline) appear in SEC Form 4 filings, and how do they reconcile with the low Insider Conviction pillar score?
  • What does the Q3 2026 earnings release (Nov. 12) disclose about revenue, cash position, and guidance?
  • What analyst consensus, price targets, and institutional ownership exist for MDWD, given that analyst and holder data are unavailable?

MDWD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MediWound Ltd. (MDWD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MDWD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MDWD Bull vs. Bear Conversation Board — What's Your Call at $13.30?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MDWD 🐻 50% BEARISH CONVICTION
1. Pick Your Side on MDWD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $14.97 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MDWD (D • RQD 51/100) a Buy at $13.86?

Welcome to the MDWD (MediWound Ltd.) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Medicinal Chemicals and Botanical Products. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $11.37 (-18.0%)
Spot @ $13.86

Pump the brakes on MDWD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MDWD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless MediWound Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $16.08 (+16.0%)
Spot @ $13.86

MDWD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MDWD, the market is fixating on short-term headline noise in Medicinal Chemicals and Botanical Products and ignoring the balance sheet and cash flow trajectory. At $13.86 (52-wk range $11.80 - $19.70), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%